Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 5/20 | 0.58 |
| ▸ | PGR | P06401 | 2/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | STS | P08842 | 6/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246984 | 1.00 | LMNA (0.64) | LMNAHSD17B1SMN1; SMN2MAPTRECQL | |
| SCHEMBL5682148 | 1.00 | LMNA (0.64) | LMNAHSD17B1SMN1; SMN2MAPTRECQL | |
| SCHEMBL5679838 | 1.00 | LMNA (0.64) | LMNAHSD17B1SMN1; SMN2MAPTRECQL | |
| SCHEMBL5679791 | 1.00 | LMNA (0.64) | LMNAHSD17B1SMN1; SMN2MAPTRECQL | |
| Methoxymethane SCHEMBL4279943 | 0.86 | ESR1 (0.60) | LMNAHSD17B1SMN1; SMN2MAPTRECQL | |
| SCHEMBL4284331 | 0.86 | LMNA (0.67) | LMNAHSD17B1SMN1; SMN2MAPTRECQL | |
| SCHEMBL1246985 | 0.86 | LMNA (0.67) | LMNAHSD17B1SMN1; SMN2MAPTRECQL | |
| Potassium Ion SCHEMBL6238010 | 0.86 | KDM4E (0.68) | LMNAHSD17B1SMN1; SMN2MAPTRECQL | |
| Potassium Ion SCHEMBL6238005 | 0.86 | KDM4E (0.68) | LMNAHSD17B1SMN1; SMN2MAPTRECQL | |
| SCHEMBL7867608 | 0.84 | ESR1 (0.63) | LMNAHSD17B1SMN1; SMN2MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6331534-B1 | ADMINISTERING EFFECTIVE AMOUNT OF STEROID WITHIN NASAL PASSAGE OF INDIVIDUAL SUCH THAT IT BINDS SPECIFICALLY TO RECEPTORS ON SURFACE OF NASAL NEUROEPITHELIAL CELLS IN VOMERONASAL ORGAN | PHERIN PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | claimed |
| US-8431559-B2 | Treatment of hot flashes | PHERIN PHARMACEUTICALS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120108558-A1 | Treatment of Hot Flashes | PHERIN PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| EP-1392320-B1 | 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS | PHERIN PHARM INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1392320-A1 | 17-METHYLENE-ANDROSTAN-3a-OL ANALOGS AS CRH INHIBITORS | Pherin Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-0830369-B1 | NOR-PREGNANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN PHARM INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030045514-A1 | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors | JULIAN N. STERN, A PROFESSIONAL CORPORATION | 2003-03-06 | — | — | US | disclosed |
| WO-2002089814-A1 | 17-METHYLENE-ANDROSTAN-3α-OL ANALOGS AS CRH INHIBITORS | PHERIN PHARMACEUTICALS, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| US-6432938-B1 | NASAL ADMINISTERING A STEROID | PHERIN CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-6331534-B1 | ADMINISTERING EFFECTIVE AMOUNT OF STEROID WITHIN NASAL PASSAGE OF INDIVIDUAL SUCH THAT IT BINDS SPECIFICALLY TO RECEPTORS ON SURFACE OF NASAL NEUROEPITHELIAL CELLS IN VOMERONASAL ORGAN | PHERIN PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| US-6117860-A | NASALLY ADMINISTERING STEROID WHICH BINDS TO A SPECIFIC NEUROEPITHELIAL RECEPTOR FOR ALLEVIATING PREMENSTRUAL TENSION AND ANXIETY | PHERIN PHARMACEUTICALS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6057439-A | EPOXYSTEROIDS | PHERIN CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5962443-A | 19-nur-pregnane steroids as neurochemical initiators of change in human hypothalamic function | PHERIN CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| US-5922699-A | AFFECTING CERTAIN CONSEQUENT BEHAVIOR AND PHYSIOLOGY, E.G., THE REDUCTION OF ANXIETY | PHERIN CORPORATION (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1996040727-A9 | NOVEL NOR-PREGNANES FOR INDUCING HYPOTHALAMIC EFFECTS | — | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108558-A1 | Treatment of Hot Flashes | HSD17B11, HSD3B1, HSD3B2 | LMNA 3777/4885HSD17B1 13/4885SMN1; SMN2 4176/4885 |
| US-20030045514-A1 | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors | CRH, CRHR1, CRHR2 | LMNA 4118/4885HSD17B1 9/4885SMN1; SMN2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.